Oral Session 3-11A AML: Clinical siginificance of genetic abnormalities

[OS3-11A-2] Clinical significance and prognostic analyses of PTPN11, RAS, and CBL mutations in pediatric AML

Taeko Kaburagi^1,2, Genki Yamato^1,2,3, Norio Shiba^2,3,4, Yusuke Hara^2,3,5, Kentaro Ohki^2,6, Manabu Sotomatsu^1,2, Hirokazu Arakawa⁵, Nobutaka Kiyokawa^2,6, Daisuke Tomizawa^2,7, Souichi Adachi^2,8, Takashi Taga^2,9, Keizo Horibe^2,3, Yasuhide Hayashi^1,2,3,10 (1.Dept. Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan., 2.Japan Children's Cancer Group, 3.Clinical Research Center, Nagoya Medical Center, Aichi, Japan., 4.Dept. Pediatrics, Yokohama City University Hospital, Kanagawa, Japan., 5.Dept. Pediatrics, Gunma University Graduate School of Medicine, Gunma, Japan., 6.Natl. Cent. For Child Health and Dev., Tokyo, Japan, 7.Div. Leukemia and Lymphoma, Children's Cancer Center, NCCHD, Tokyo, Japan., 8.Human Health Science, Kyoto University, Kyoto, Japan., 9.Dept. Pediatrics, Shiga University of Medical Science, Shiga, Japan., 10.Institute of Physiology and Medicine, Jobu University)